A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our signal to daydream about weekend plans. Our agenda is rather modest. We hope to spend time with a couple of our short people, engage the official mascots, and catch up on our reading. And what about you? Summer is nearing an end, so perhaps you can take one last jaunt to the ocean or lake. You could also prepare for autumn and purchase a sweater or rake. Or you could check to see if anyone has written any anonymous missives about you. Well, whatever you do, have a grand time. But be safe. By the way, we will be gone until Wednesday while we observe ancient traditions. A colleague will forward the newsletter to you in our absence. Meanwhile, enjoy …

Trump administration restrictions on hiring those who have lived outside of the U.S. is making it difficult for the Food and Drug Administration to attract top talent, STAT writes. The policy “definitely has created an additional challenge, I think, for us. The U.S. just doesn’t graduate the number that we need to fill our vacancies,” says Melanie Keller, acting associate commissioner for scientific and clinical recruitment. The agency must restrict the number of offers of employment they make to people who have lived outside the U.S. for three of the past five years.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Unless this patent was filed simultaneously with the one for Oxycontin, I find the ‘moral outrage’ pedantic at best. “The idea Sackler “could get richer” from the patent was “very disturbing,” says Andrew Kolodny…”
    Next some will say it’s disturbing for the head of HHS to have worked for Lilly for many years … oh, wait!

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy